Auszug
Grundsätzlich sollte der Patient vor jeglicher Behandlung eines kutanen Lupus erythematodes (LE) auf systemische Manifestation untersucht werden (entsprechend den revidierten ARA-Kriterien).
Preview
Unable to display preview. Download preview PDF.
Literatur
- Fabbri P, Cardinali C, Giomi B, Caroni M (2003) Cutaneous Lupus Erythematosus. Am J Clin Dermatol 4:449–465PubMedCrossRefGoogle Scholar
- Petri M (2004) Cyclophosphamide: new approaches for systemic lupus erythematosus. Lupus 13:366–371PubMedCrossRefGoogle Scholar
- Gaubitz M, Schorat A, Schotte H et al. (1999) Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 8:731–736PubMedCrossRefGoogle Scholar
Literatur
- Aberer W, Wolff-Schreiner EC, Stingl G, Wolff K (1987) Azathioprine in the treatment of pemphigus vulgaris. J Am Acad Dermatol 16:527–533PubMedGoogle Scholar
- Beissert S, Werfel T, Frieling U, Böhm M, Sticherling M, Stadler R, Zillikens D, Rzany B, Hunzelmann N, Meurer M, Gollnick H, Ruzicka T, Pillekamp H, Junghans V, Luger TA (2007) A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Im Druck.Google Scholar
- Blumenfeld Z, Haim N (1997) Prevention of gonadal damage during cytotoxic therapy. Ann Med 29:199–206PubMedGoogle Scholar
- Buchanan NM, Toubi E, Khamashta MA, Lima F, Kerslake S, Hughes GR (1996) Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis 55:486–488PubMedCrossRefGoogle Scholar
- Chan TM, Li FK, Tang CS et al. (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 343:1156–1162PubMedCrossRefGoogle Scholar
- D’Cruz D, Cuadrado MJ, Mujic F et al. (1997) Immunosuppressive therapy in lupus nephritis. Clin Exp Rheumatology 15: 275–282Google Scholar
- Fiedler A et al. (1998) The royal college of ophthalmologists guidelines: ocular toxicity and hydroxychloroquin. Eye 12: 907–908Google Scholar
- Fine JD (1995) Management of acquired bullous skin diseases. N Engl J Med 333:1475–1484PubMedCrossRefGoogle Scholar
- Fivenson DP, Breneman DL, Rosen GB, Craig SH, Cardone S, Mutasim D (1994) Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 130:753–758PubMedCrossRefGoogle Scholar
- Goebeler M, Sitaru C, Zillikens D (2004) Bullöse Autoimmundermatosen (II): Therapie. JDDG 2:123–139PubMedCrossRefGoogle Scholar
- Ioannides D, Chrysomallis F, Bystryn J (2000) Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol 136:868–872PubMedCrossRefGoogle Scholar
- Joly P, Roujeau JC, Benichou J et al. (2002) A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 346:321–327PubMedCrossRefGoogle Scholar
- Riuz-Irastorza G, Khamashta MA, Hughes GR (2001) Antiaggregant and anticoagulant therapy in systemic lupus erythematosus and Hughes syndrome. Lupus 10:241–245CrossRefGoogle Scholar
- Schmidt E, Hunzelmann N, Zillikens D, Brocker EB, Goebeler M (2006) Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol 31:503–508PubMedCrossRefGoogle Scholar
- Takada K, Illei GG, Boumpas DT (2001) Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 10: 154–161PubMedCrossRefGoogle Scholar
- Vennig VA, Millard PR, Wojnarowska F(1989) Dapsone as first line therapy for bullous pemphigoid. Br J Dermatol 120:83–92CrossRefGoogle Scholar
- Zillikens D. Bullöse Autoimmundermatosen. In: Braun-Falco O, Plewig G, Wolff HH, Burgdorf W, Landthaler M (Hrsg.). Dermatologie, 5. Auflage. Springer, Heidelberg Berlin 2005, pp 607–638Google Scholar
Copyright information
© Springer Medizin Verlag Heidelberg 2007